Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s Reassessment and Uptake Working Group

The Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) Collaboration was established to develop a framework for generating and using real-world evidence (RWE) to inform the reassessment of cancer drugs following initial health technology assessment (HTA). The Reassessment and Uptake...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Wei Fang, Arciero, Vanessa, Craig, Erica, Fraser, Brent, Arias, Jessica, Boehm, Darryl, Bosnic, Nevzeta, Caetano, Patricia, Chambers, Carole, Jones, Barry, Lungu, Elena, Mitera, Gunita, Potashnik, Tanya, Reiman, Anthony, Ritcher, Trevor, Beca, Jaclyn M., Denburg, Avram, Mercer, Rebecca E., Parmar, Ambica, Tadrous, Mina, Takhar, Pam, Chan, Kelvin K. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534602/
https://www.ncbi.nlm.nih.gov/pubmed/34677272
http://dx.doi.org/10.3390/curroncol28050354

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534602/
https://www.ncbi.nlm.nih.gov/pubmed/34677272
http://dx.doi.org/10.3390/curroncol28050354

Ejemplares similares